Skip to main content
Top
Published in: Respiratory Research 1/2013

Open Access 01-12-2013 | Review

COPD symptoms in the morning: impact, evaluation and management

Authors: Nicolas Roche, Niels H Chavannes, Marc Miravitlles

Published in: Respiratory Research | Issue 1/2013

Login to get access

Abstract

Chronic obstructive pulmonary disease (COPD) symptoms in the morning, including dyspnea and sputum production, affect patients’ quality of life and limit their ability to carry out even simple morning activities. It is now emerging that these symptoms are associated with increased risk of exacerbations and work absenteeism, suggesting that they have a more profound impact on patients than previously thought. The development of validated patient-reported outcome (PRO) questionnaires to capture patients’ experience of COPD symptoms in the morning is, therefore, vital for establishing effective and comprehensive management strategies. Although it is well established that long-acting bronchodilators are effective in improving COPD symptoms, the limited available data on their impact on morning symptoms and activities have been obtained with non-validated PRO questionnaires. In this review, we discuss the impact of COPD symptoms in the morning and available tools used to evaluate them, and highlight specific gaps that need to be addressed to develop standardized instruments able to meet regulatory requirement. We also present available evidence on the effect of pharmacological therapies on morning symptoms.
Appendix
Available only for authorised users
Literature
2.
go back to reference Fletcher MJ, Upton J, Taylor-Fishwick J, Buist SA, Jenkins C, Hutton J, Barnes N, Van Der Molen T, Walsh JW, Jones P, Walker S: COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health. 2011, 11: 612-10.1186/1471-2458-11-612.PubMedPubMedCentralCrossRef Fletcher MJ, Upton J, Taylor-Fishwick J, Buist SA, Jenkins C, Hutton J, Barnes N, Van Der Molen T, Walsh JW, Jones P, Walker S: COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health. 2011, 11: 612-10.1186/1471-2458-11-612.PubMedPubMedCentralCrossRef
3.
go back to reference Partridge MR, Karlsson N, Small IR: Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009, 25: 2043-2048. 10.1185/03007990903103006.PubMedCrossRef Partridge MR, Karlsson N, Small IR: Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009, 25: 2043-2048. 10.1185/03007990903103006.PubMedCrossRef
4.
go back to reference O'Donnell DE, Laveneziana P: The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006, 3: 219-232. 10.1080/15412550600977478.PubMedCrossRef O'Donnell DE, Laveneziana P: The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006, 3: 219-232. 10.1080/15412550600977478.PubMedCrossRef
5.
go back to reference Laveneziana P, Parker CM, O'Donnell DE: Ventilatory constraints and dyspnea during exercise in chronic obstructive pulmonary disease. Appl Physiol Nutr Metab. 2007, 32: 1225-1238. 10.1139/H07-119.PubMedCrossRef Laveneziana P, Parker CM, O'Donnell DE: Ventilatory constraints and dyspnea during exercise in chronic obstructive pulmonary disease. Appl Physiol Nutr Metab. 2007, 32: 1225-1238. 10.1139/H07-119.PubMedCrossRef
6.
go back to reference Higgins V, Broomfield S, Pollard R, Fermer S: Impact of morning symptoms on the working lives of COPD patients. 2012, Birmingham, UK: International Conference for Chronic Obstructive Pulmonary Disease, Abstract Higgins V, Broomfield S, Pollard R, Fermer S: Impact of morning symptoms on the working lives of COPD patients. 2012, Birmingham, UK: International Conference for Chronic Obstructive Pulmonary Disease, Abstract
7.
go back to reference Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J: Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011, 37: 264-272. 10.1183/09031936.00051110.PubMedCrossRef Kessler R, Partridge MR, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D, Ostinelli J: Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011, 37: 264-272. 10.1183/09031936.00051110.PubMedCrossRef
8.
go back to reference Small M, Broomfield M, Pollard R, Fermer S: Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler use and normal daily activities. Eur Resp J. 2012, 40 (56): 3476-Abstract Small M, Broomfield M, Pollard R, Fermer S: Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler use and normal daily activities. Eur Resp J. 2012, 40 (56): 3476-Abstract
9.
go back to reference Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl CG, Partridge MR: Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest. 2006, 130: 133-142. 10.1378/chest.130.1.133.PubMedCrossRef Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl CG, Partridge MR: Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest. 2006, 130: 133-142. 10.1378/chest.130.1.133.PubMedCrossRef
10.
go back to reference van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ: Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006, 129: 509-517. 10.1378/chest.129.3.509.PubMedCrossRef van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ: Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006, 129: 509-517. 10.1378/chest.129.3.509.PubMedCrossRef
11.
go back to reference Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S: Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003, 58: 855-860. 10.1136/thorax.58.10.855.PubMedPubMedCentralCrossRef Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S: Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003, 58: 855-860. 10.1136/thorax.58.10.855.PubMedPubMedCentralCrossRef
12.
go back to reference McCarley C, Hanneman SK, Padhye N, Smolensky MH: A pilot home study of temporal variations of symptoms in chronic obstructive lung disease. Biol Res Nurs. 2007, 9: 8-20. 10.1177/1099800407303501.PubMedCrossRef McCarley C, Hanneman SK, Padhye N, Smolensky MH: A pilot home study of temporal variations of symptoms in chronic obstructive lung disease. Biol Res Nurs. 2007, 9: 8-20. 10.1177/1099800407303501.PubMedCrossRef
13.
go back to reference Kuyucu T, Guclu SZ, Saylan B, Demir C, Senol T, Guner S, Koyuncu E, Ozen F, Ozturk S, Cangul Z, Aganoglu S, Ozkaya S, Ocak SC, Akkurt H, Intepe YS, Bayrak MG, Guler T, Bekci TT, Soyyigit S, Seyfettin S, Kula O, Akbay MO, Buyukgoze B, Asal G, Baslilar S, Ozturk O: A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study. Tuberk Toraks. 2011, 59: 328-339. 10.5578/tt.3268.PubMedCrossRef Kuyucu T, Guclu SZ, Saylan B, Demir C, Senol T, Guner S, Koyuncu E, Ozen F, Ozturk S, Cangul Z, Aganoglu S, Ozkaya S, Ocak SC, Akkurt H, Intepe YS, Bayrak MG, Guler T, Bekci TT, Soyyigit S, Seyfettin S, Kula O, Akbay MO, Buyukgoze B, Asal G, Baslilar S, Ozturk O: A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study. Tuberk Toraks. 2011, 59: 328-339. 10.5578/tt.3268.PubMedCrossRef
14.
go back to reference Kim YJ, Lee BK, Jung CY, Jeon YJ, Hyun DS, Kim KC, Yu SK, Choi HS, Shin WH, Lee KH: Patient's perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL study. Korean J Intern Med. 2012, 27: 426-435. 10.3904/kjim.2012.27.4.426.PubMedPubMedCentralCrossRef Kim YJ, Lee BK, Jung CY, Jeon YJ, Hyun DS, Kim KC, Yu SK, Choi HS, Shin WH, Lee KH: Patient's perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL study. Korean J Intern Med. 2012, 27: 426-435. 10.3904/kjim.2012.27.4.426.PubMedPubMedCentralCrossRef
15.
go back to reference Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010, 363: 1128-1138. 10.1056/NEJMoa0909883.PubMedCrossRef Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010, 363: 1128-1138. 10.1056/NEJMoa0909883.PubMedCrossRef
16.
go back to reference Miravitlles M, Llor C, de Castellar R, Izquierdo I, Baro E, Donado E: Validation of the COPD severity score for use in primary care: the NEREA study. Eur Respir J. 2009, 33: 519-527. 10.1183/09031936.00087208.PubMedCrossRef Miravitlles M, Llor C, de Castellar R, Izquierdo I, Baro E, Donado E: Validation of the COPD severity score for use in primary care: the NEREA study. Eur Respir J. 2009, 33: 519-527. 10.1183/09031936.00087208.PubMedCrossRef
17.
go back to reference Partridge MR, Miravitlles M, Stahl E, Karlsson N, Svensson K, Welte T: Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J. 2010, 36: 96-104. 10.1183/09031936.00123709.PubMedCrossRef Partridge MR, Miravitlles M, Stahl E, Karlsson N, Svensson K, Welte T: Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J. 2010, 36: 96-104. 10.1183/09031936.00123709.PubMedCrossRef
18.
go back to reference Food US, Administration D: Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Fed Regist. 2009, 74: 65132-65133. Food US, Administration D: Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Fed Regist. 2009, 74: 65132-65133.
19.
go back to reference Palsgrove A, Houghton K, Hareendran A, Scaefer M, Setyawan J, Mocarski M: The development of the early morning symptoms of COPD instrument (EMSCI). Value Health. 2011, 14 (7): A496-A497. Abstract PRS51CrossRef Palsgrove A, Houghton K, Hareendran A, Scaefer M, Setyawan J, Mocarski M: The development of the early morning symptoms of COPD instrument (EMSCI). Value Health. 2011, 14 (7): A496-A497. Abstract PRS51CrossRef
20.
go back to reference Kinsman RA, Yaroush RA, Fernandez E, Dirks JF, Schocket M, Fukuhara J: Symptoms and experiences in chronic bronchitis and emphysema. Chest. 1983, 83: 755-761. 10.1378/chest.83.5.755.PubMedCrossRef Kinsman RA, Yaroush RA, Fernandez E, Dirks JF, Schocket M, Fukuhara J: Symptoms and experiences in chronic bronchitis and emphysema. Chest. 1983, 83: 755-761. 10.1378/chest.83.5.755.PubMedCrossRef
21.
go back to reference Reishtein JL: Relationship between symptoms and functional performance in COPD. Res Nurs Health. 2005, 28: 39-47. 10.1002/nur.20054.PubMedCrossRef Reishtein JL: Relationship between symptoms and functional performance in COPD. Res Nurs Health. 2005, 28: 39-47. 10.1002/nur.20054.PubMedCrossRef
22.
go back to reference Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia GE, Caracta CF: Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012, 9: 90-101. 10.3109/15412555.2012.661492.PubMedCrossRef Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia GE, Caracta CF: Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012, 9: 90-101. 10.3109/15412555.2012.661492.PubMedCrossRef
23.
go back to reference Miravitlles M, Iriberri M, Barrueco M, Lleonart M, Villarrubia E, Galera J: Usefulness of the LCOPD, CAFS and CASIS Scales in understanding the impact of COPD on Patients. Respiration. 2012, [Epub ahead of print]: doi:10.1159/000341175. Miravitlles M, Iriberri M, Barrueco M, Lleonart M, Villarrubia E, Galera J: Usefulness of the LCOPD, CAFS and CASIS Scales in understanding the impact of COPD on Patients. Respiration. 2012, [Epub ahead of print]: doi:10.1159/000341175.
24.
go back to reference Beier J, Kirsten AM, Mruz R, Segarra R, Chuecos F, Caracta C, Gil EG: Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013, 10: 511-522. 10.3109/15412555.2013.814626.PubMedPubMedCentralCrossRef Beier J, Kirsten AM, Mruz R, Segarra R, Chuecos F, Caracta C, Gil EG: Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013, 10: 511-522. 10.3109/15412555.2013.814626.PubMedPubMedCentralCrossRef
25.
go back to reference Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falques M, Caracta CF, Garcia GE: Efficacy of aclidinium bromide 400 mug twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest. 2012, 141: 745-752. 10.1378/chest.11-0406.PubMedCrossRef Fuhr R, Magnussen H, Sarem K, Llovera AR, Kirsten AM, Falques M, Caracta CF, Garcia GE: Efficacy of aclidinium bromide 400 mug twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest. 2012, 141: 745-752. 10.1378/chest.11-0406.PubMedCrossRef
26.
go back to reference Welte T, Metzenauer P, Hartmann U: Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD–a double-blind, randomised, controlled trial. Pulm Pharmacol Ther. 2008, 21: 4-13. 10.1016/j.pupt.2006.09.002.PubMedCrossRef Welte T, Metzenauer P, Hartmann U: Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD–a double-blind, randomised, controlled trial. Pulm Pharmacol Ther. 2008, 21: 4-13. 10.1016/j.pupt.2006.09.002.PubMedCrossRef
27.
go back to reference Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002, 19: 217-224. 10.1183/09031936.02.00269802.PubMedCrossRef Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002, 19: 217-224. 10.1183/09031936.02.00269802.PubMedCrossRef
28.
go back to reference Cazzola M, Molimard M: The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010, 23: 257-267. 10.1016/j.pupt.2010.03.003.PubMedCrossRef Cazzola M, Molimard M: The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010, 23: 257-267. 10.1016/j.pupt.2010.03.003.PubMedCrossRef
29.
go back to reference Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B: Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010, 65: 473-479. 10.1136/thx.2009.125435.PubMedCrossRef Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B: Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010, 65: 473-479. 10.1136/thx.2009.125435.PubMedCrossRef
30.
go back to reference Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B: Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010, 182: 155-162. 10.1164/rccm.200910-1500OC.PubMedCrossRef Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B: Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010, 182: 155-162. 10.1164/rccm.200910-1500OC.PubMedCrossRef
31.
go back to reference Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B: Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011, 37: 273-279. 10.1183/09031936.00045810.PubMedCrossRef Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B: Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011, 37: 273-279. 10.1183/09031936.00045810.PubMedCrossRef
32.
go back to reference Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001, 164: 778-784. 10.1164/ajrccm.164.5.2007006.PubMedCrossRef Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001, 164: 778-784. 10.1164/ajrccm.164.5.2007006.PubMedCrossRef
33.
go back to reference Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T: Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis. 2009, 3: 1-11.PubMedCrossRef Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T: Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis. 2009, 3: 1-11.PubMedCrossRef
34.
go back to reference Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia GE: Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012, 40: 830-836. 10.1183/09031936.00225511.PubMedCrossRef Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia GE: Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012, 40: 830-836. 10.1183/09031936.00225511.PubMedCrossRef
35.
go back to reference Kerwin E, Rennard S, Gelb S: Twice-daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in Accord COPD I. Am J Respir Crit Care Med. 2011, 183: A1592- Kerwin E, Rennard S, Gelb S: Twice-daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in Accord COPD I. Am J Respir Crit Care Med. 2011, 183: A1592-
36.
go back to reference Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, Caracta C: Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med. 2011, 105: 580-587. 10.1016/j.rmed.2010.11.019.PubMedCrossRef Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, Caracta C: Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med. 2011, 105: 580-587. 10.1016/j.rmed.2010.11.019.PubMedCrossRef
37.
go back to reference Singh D, Bateman ED, Jones PW: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). Eur Resp J. 2011, 38 (Suppl. 55): 875- Singh D, Bateman ED, Jones PW: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD). Eur Resp J. 2011, 38 (Suppl. 55): 875-
38.
go back to reference Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG: Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD. 2010, 7: 331-336. 10.3109/15412555.2010.510158.PubMedCrossRef Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG: Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD. 2010, 7: 331-336. 10.3109/15412555.2010.510158.PubMedCrossRef
39.
go back to reference Agusti J, Jones PW, Bateman E: Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN. Eur Resp J. 2011, 38 (Suppl. 55): 874- Agusti J, Jones PW, Bateman E: Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN. Eur Resp J. 2011, 38 (Suppl. 55): 874-
40.
go back to reference D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011, 12: 156-10.1186/1465-9921-12-156.PubMedPubMedCentralCrossRef D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011, 12: 156-10.1186/1465-9921-12-156.PubMedPubMedCentralCrossRef
41.
go back to reference Fogarty C, Hattersley H, Di Scala L, Drollmann A: Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2011, 105: 337-342. 10.1016/j.rmed.2010.10.021.PubMedCrossRef Fogarty C, Hattersley H, Di Scala L, Drollmann A: Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2011, 105: 337-342. 10.1016/j.rmed.2010.10.021.PubMedCrossRef
42.
go back to reference Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D: Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012, 40: 1106-1114. 10.1183/09031936.00040712.PubMedPubMedCentralCrossRef Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D: Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012, 40: 1106-1114. 10.1183/09031936.00040712.PubMedPubMedCentralCrossRef
43.
go back to reference Verkindre C, Fukuchi Y, Flemale A, Takeda A, Overend T, Prasad N, Dolker M: Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010, 104: 1482-1489. 10.1016/j.rmed.2010.04.006.PubMedCrossRef Verkindre C, Fukuchi Y, Flemale A, Takeda A, Overend T, Prasad N, Dolker M: Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2010, 104: 1482-1489. 10.1016/j.rmed.2010.04.006.PubMedCrossRef
44.
go back to reference Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Guclu SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK: Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010, 23: 438-444. 10.1016/j.pupt.2010.04.005.PubMedCrossRef Vogelmeier C, Verkindre C, Cheung D, Galdiz JB, Guclu SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK: Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010, 23: 438-444. 10.1016/j.pupt.2010.04.005.PubMedCrossRef
45.
go back to reference Beeh K, Singh D, Di Scala L: Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012, 7: 513-515. Beeh K, Singh D, Di Scala L: Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012, 7: 513-515.
46.
go back to reference Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, Banerji D: Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013 Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, Banerji D: Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013
47.
go back to reference NCT01712516: A 12-week treatment, multi-center, randomized, double-blind, parallel-group, placebo and active controlled study to assess the efficacy, safety, and tolerability of indacaterol maleate / glycopyrronium bromide in COPD patients with moderate to severe airflow limitation. 2013, http://clinicaltrials.gov/ct2/results?term=NCT+01712516; Last accessed 18 NCT01712516: A 12-week treatment, multi-center, randomized, double-blind, parallel-group, placebo and active controlled study to assess the efficacy, safety, and tolerability of indacaterol maleate / glycopyrronium bromide in COPD patients with moderate to severe airflow limitation. 2013, http://​clinicaltrials.​gov/​ct2/​results?​term=​NCT+01712516; Last accessed 18
48.
go back to reference Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R: Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009, 180: 741-750. 10.1164/rccm.200904-0492OC.PubMedCrossRef Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R: Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009, 180: 741-750. 10.1164/rccm.200904-0492OC.PubMedCrossRef
Metadata
Title
COPD symptoms in the morning: impact, evaluation and management
Authors
Nicolas Roche
Niels H Chavannes
Marc Miravitlles
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2013
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-14-112

Other articles of this Issue 1/2013

Respiratory Research 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.